Healthcare
ByIs Short-Term Cost Control Undermining Long-Term Innovation? Novartis Calls for Structural Reform in Global Healthcare
23 January 2026 Executive Summary Novartis has issued a call for structural reform in global healthcare policy, warning…
Is Regional Distribution Becoming a Strategic Lever for Big Pharma? Novartis Expands European Reach Through Malta Partnership
23 January 2026 Executive Summary Novartis Pharma Services AG has entered into a strategic distribution agreement with Vivian…
Can Localized Manufacturing Shield Big Pharma from Trade Volatility? Novartis Targets Zero U.S. Tariff Exposure by Mid-2026
23 January 2026 Executive Summary Novartis CEO Vas Narasimhan has outlined a decisive trade-risk mitigation strategy, stating that…
Is U.S. Manufacturing the Next Growth Hedge for Big Pharma? Novartis Commits $23 Billion to Domestic Expansion
23 January 2026 Executive Summary Novartis has unveiled a $23 billion investment plan to significantly expand its U.S.…
BioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150 Layoffs Amid 5-10% Demand Drop
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production of its HPV…
Merck’s Bold Pivot: Can Dividing Oncology from the Rest Save Keytruda’s Legacy?
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere corporate tinkering—it’s a…
